WHO finally prequalifies first malaria drug for infants, years after the disease claimed hundreds of thousands of young lives

The World Health Organization has granted prequalification to Coartem Baby, the first antimalarial formulation expressly authorized for infants under six months, thereby creating a formal pathway for its deployment in malaria‑endemic regions. This decision arrives against a backdrop in which recent surveillance indicates that up to eighteen percent of children younger than six months in certain African locales test positive for malaria, a statistic that starkly contrasts with the historic absence of a therapeutically approved option for this vulnerable cohort.

While the prequalification represents a regulatory milestone, it also implicitly acknowledges that the global health architecture has, for decades, tolerated a therapeutic void that contributed to the 610,000 malaria deaths recorded in 2024, three quarters of which occurred among children under five in Africa. The protracted interval between the recognition of infant susceptibility and the eventual WHO endorsement underscores a procedural inertia that routinely favours adult formulations, leaving the smallest patients dependent on off‑label use of drugs designed for older children, a practice that has long been contested by paediatric experts. Consequently, the imminent rollout of Coartem Baby will inevitably confront the same logistical bottlenecks, funding gaps, and supply‑chain fragilities that have historically hampered the distribution of even well‑established malaria interventions.

In a health ecosystem where disease burden quantification routinely precedes therapeutic innovation, the belated approval of a drug for the youngest sufferers serves less as a triumph of scientific progress than as a reminder of institutional complacency that permits preventable mortality to persist under the guise of gradual improvement. The episode thus highlights the paradox that, while global health authorities can eventually endorse life‑saving medicines, they often do so only after the mortality statistics have already underscored the urgency, thereby converting avoidable deaths into a pre‑condition for policy action.

Published: May 2, 2026